A new scientific review reveals that GLP-1 receptor agonists, best known for treating diabetes and obesity, could have a significant impact on musculoskeletal health. Researchers found these drugs may reduce inflammation and oxidative stress in joints, potentially slowing the progression of osteoarthritis and preserving cartilage.
In bone, GLP-1 signaling appears to inhibit bone breakdown while promoting bone formation, suggesting a protective role during rapid weight loss. For muscle, while some lean mass is lost, the quality of remaining tissue may improve due to enhanced mitochondrial function and insulin sensitivity.
Spinal health also stands to benefit: preclinical models show GLP-1 drugs can slow intervertebral disc degeneration and reduce low back pain, likely by lowering inflammation and mechanical load on the spine. However, experts call for more rigorous clinical trials to confirm these effects and determine if next-generation multi-hormone agonists can act as true disease-modifying treatments.